The Epitomical 'Mover & Shaker'

A Special Issue of the European Journal of Neuroscience has been put together by NECTAR (Network for European CNS Transplantation & Restoration) in collaboration with The Cure Parkinson’s Trust (CPT) in memory of late President and Co-founder Tom Isaacs who sadly passed away suddenly last year.

Tom was a whirlwind of wit and energy who used his young onset Parkinson’s to try and change our thinking and approach to this condition, and who succeeded in changing the landscape on how we treat this condition, forever and for the better.

CPT is delighted to see some superb extracts of research articles being published online as part of the lead up to this EJN Special Edition which will be published in full in late December early January.

We will be publishing some articles 'free to read' in full, and this article by Tom's wife Lyndsey Isaacs and neurologist Prof. Roger Barker heralds the collaboration.

Latest

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned...

Related

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned...

When misfolded, the protein alpha-synuclein becomes toxic to neurons and is a key pathological culprit in Parkinson’s. It is therefore an important target for disease-modification. Immunotherapy in Parkinson's attempts to use immune cells, and specifically the antibodies they generate, to target misfolded alpha-synuclein to inactivate it.

Soania Mathur was, like former President of CPT Tom Isaacs, diagnosed with Young Onset Parkinson's at just 27. For Soania, Tom’s core principles of supporting people with Parkinson’s in becoming active participants in the search for better treatments, key to finding a cure.

Researchers at the Johns Hopkins School of Medicine have published a research report that points not only towards a specific pathway of neurodegeneration for Parkinson's, but also highlights a therapeutic target for which clinically-approved drugs are already available.

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...

The human appendix was long considered functionless and a bit of an oddity. Some people even thought of it as an accident of evolution. More recently, however, our ideas regarding the appendix have changed. And a new study published this week suggests that the appendix may even be influential in some cases of Parkinson's.

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.